IndustryCompany release

Puma Biotechnology Q3 net income falls to $6.0M but company raises 2026 profit guidance

🇺🇸 Puma Biotechnology, Inc. (PBYI) · Thu 05 Nov 2026

Higher Medicaid and 340B deductions and increased R&D spending cut profit, even as NERLYNX sales grew; Puma also began a Phase II lung cancer trial.

Puma Biotechnology reported third-quarter 2026 results on 5 November. Total revenue was $55.1M, of which net NERLYNX product revenue was $54.1M, up from $51.9M in the comparison figure given by the company.

Net income came to $6.0M, down from $8.8M. Puma attributed the decline to higher gross-to-net deductions linked to Medicaid and 340B sales, together with higher research and development spending.

Despite the lower quarterly profit, the company raised its net income guidance for 2026. The summary of the announcement does not give the revised figures.

On the pipeline, Puma has started ALISCA-Lung2, a Phase II trial of alisertib combined with paclitaxel in small cell lung cancer. The company also plans to discuss a Phase III design for alisertib in breast cancer with regulators in the first half of 2027.

What it means for your team

  • Market access teams: the results show how Medicaid and 340B channel mix can erode net profit even when net product revenue is growing.
  • Regulatory teams: Puma's planned H1 2027 discussions with regulators on a Phase III design will be an early indicator of the development path for alisertib in breast cancer.
  • Clinical and portfolio watchers: ALISCA-Lung2 adds a small cell lung cancer programme for alisertib alongside the breast cancer work.

Company's press release (SEC filing): Puma Biotechnology, Inc. ↗

Article written by VigiEye from the official source (Puma Biotechnology, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →